Caspofungin: When and how? The microbiologist's view

Mycoses

Volumn 55, Issue 1, 2012, Pages 27-35

  Mayr, Astrid ^a   Aigner, Maria ^a   Lass Flörl, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Aspergillus; Breakthrough infections; Candida; Caspofungin; Treatment

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CYCLOSPORIN; FLUCONAZOLE; GLUCAN SYNTHASE; ITRACONAZOLE; MICAFUNGIN; POLYENE; PYRROLE; RIFAMPICIN; SULFAMETHOXAZOLE; TRIMETHOPRIM; VORICONAZOLE;

CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; DRUG EXPOSURE; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INVASIVE ASPERGILLOSIS; LOADING DRUG DOSE; MENINGITIS; MICROBIOLOGY; MUCORMYCOSIS; MUTATION; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PATIENT CARE; PNEUMOCYSTIS JIROVECI; PNEUMONIA; PRIORITY JOURNAL; REVIEW; TRICHOSPORON BEIGELII;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; BETA-GLUCANS; BIOFILMS; CANDIDA; CANDIDIASIS; CELL WALL; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GLUCOSYLTRANSFERASES; GUIDELINES AS TOPIC; HUMANS;

ASPERGILLUS; CANDIDA; CANDIDA GLABRATA; ISSATCHENKIA ORIENTALIS;

EID: 83655201480     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02039.x     Document Type: Review

References (82)

1. Anaissie E, Bodey GP. Nosocomial fungal infections. Old problems and new challenges. Infect Dis Clin North Am 1989; 3: 867-82.
2. Bodey GP, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: an international autopsy study. Eur J Clin Microbiol Infect Dis 1992; 11: 99-109.
3. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805.
4. Pfaller M, Pappas P, Wingard J. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006; 43: 3-14.
5. Steinbach W, Stevens D, Denning DW. Combination and sequential therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1996 to 2001. Clin Infect Dis 2003; 37: S188-224.
6. Upton A, Marr KA. Emergence of opportunistic mould infections in the hematopoetic stem cell transplant patient. Curr Infect Dis 2006; 8: 434-41.
7. Almyroudis N, Sutton D, Linden P, Rinaldi M, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6: 2365-75.
8. Bonatti H, Goegele H, Tabarelli D et al. Pseudallescheria boydii infection after liver retransplantation. Liver Transpl 2007; 13: 1068-9.
9. Fridkin S. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41: 1455-60.
10. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851-6.
11. Lass-Flörl C, Griff K, Mayr A et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131: 201-7.
12. Vigouroux S, Morin O, Moreau P et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005; 40: 35-37.
13. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
14. Bal AM. The echinocandins: three useful choices or three too many? Int J Antimicrob Agents 2010; 35: 13-18.
15. Kauffman CA. Echinocandins. What role in the future? Infect Dis Clin Pract 2005; 13: 149-51.
16. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009; 53: 112-22.
17. Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008; 14: 487-94.
18. Swinne D, Nolard N, van Rooij P, Detandt M. Bloodstream yeast infections: a 15-month survey. Epidemiol Infect 2009; 137: 1037-40.
19. Keating GM, Figgitt DP. Caspofungin. A review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs 2003; 63: 2235-63.
20. Ernst EJ, Klepser ME, Ernst ME et al. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999; 33: 75-80.
21. Pfaller MA, Oyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2, 500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43: 5425-7.
22. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3, 959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003; 47: 1068-71.
23. Kabbara N, Lacroix C, Peffault de Latour R, Socié G, Ghannoum M, Ribaud P. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogenic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 2008; 93: 639-40.
24. Cheung C, Guo Y, Gialanella P, Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection 2006; 34: 345-8.
25. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56: 126-9.
26. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12, 052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-36.
27. Kurtz MB, Heath IB, Marrinan J et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1, 3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-9.
28. Manavathu EK, Ramesh MS, Baskarab I, Ganesan LT, Chandrasekar PH. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004; 53: 386-9.
29. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56952 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-6.
30. Pfaller MA, Marco F, Messer SA et al. In vitro activity of two echinocandin derivates, LY303366 and MK-0991 (L-743, 792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251-5.
31. Hof H, Schnülle P. Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated efficiently with caspofungin. Mycoses 2008; 51: 65-67.
32. Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhino-orbital cerebral mucormycosis. Clin Infect Dis 2008; 47: 364-71.
33. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
34. Ramage G, Bachmann S, Patterson TF, Wickes BL, López-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002; 49: 973-80.
35. Mukherjee PK, Chandra J. Candida biofilm resistance. Drug Resist Updat 2004; 7: 301-9.
36. Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997; 43: 405-16.
37. Choi HW, Shin JH, Jung SI et al. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob Agents Chemother 2007; 51: 1520-3.
38. Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 2008; 62: 153-5.
39. Shuford JA, Piper KE, Steckelberg JM, Patel R. In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates. Diagn Microbiol Infect Dis 2007; 57: 277-81.
40. Tobudic S, Kratzer C, Lassnigg A, Graninger W, Presterl E. In vitro activity of antifungal combinations against Candida albicans biofilms. J Antimicrob Chemother 2010; 65: 271-4.
41. Reese AJ, Yoneda A, Breger JA et al. Loss of cell wall α (1-3) glucan affects Cryptococcus neoformans from ultrastructure to virulence. Mol Microbiol 2007; 63: 1385-98.
42. Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-73.
43. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentration of antifungal agents for conidia-forming mould. Clin Microbiol Infect 2008; 14: 982-4.
44. Arendrup MC, Perkhofer S, Howard SJ et al. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 2008; 52: 3504-11.
45. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 2006; 50: 2892-4.
46. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57: 705-8.
47. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42: 938-44.
48. Madureira A, Bergeron A, Lacroix C et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007; 30: 551-4.
49. Thompson GR 3rd, Wiederhold NP, Vallor AC, Villareal NC, Lewis JS 2nd, Patterson TF. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 2008; 52: 3783-5.
50. Ramos A, Cuervas-Mons V, Noblejas A et al. Breakthrough rhinocerebral mucormycosis in a liver transplant patient receiving caspofungin. Transpl Proc 2009; 41: 1972-5.
51. Goodman D, Pamer E, Jakubowski A, Morris C, Sepkowitz K. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 2002; 35: E35-E36.
52. Kurtz MB, Abruzzo G, Flattery A et al. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun 1996; 64: 3244-51.
53. Ghannoum M, D'Angelo M. Anidulafungin: a potent antifungal that targets Candida and Aspergillus. Infect Dis Clin Pract 2005; 13: 149-51.
54. Maertens J, Boogaerts M. Caspofungin in the treatment of candidosis and aspergillosis. Int J Infect Dis 2003; 7: 94-101.
55. Stone EA, Fung HB, Kirschenbaum HL. Caspofungin: an echinocandin antifungal agent. Clin Ther 2002; 24: 351-77.
56. Sans-Rodriguez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclsporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34: 13-20.
57. Azanza JR, Montejo M. Pharmacokinetics and pharmacodynamics: interactions and adverse effects. Comparison with other echinocandins. Enferm Infect Microbiol Clin 2008; 26: 14-20.
58. Stone JA, Migoya EM, Hickey L et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004; 48: 4306-14.
59. McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005; 65: 2049-68.
60. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
61. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
62. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-9.
63. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46: 451-7.
64. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71.
65. Viscoli C, Herbrecht R, Akan H et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64: 1274-81.
66. Herbrecht R, Maertens J, Baila L et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45: 1227-33.
67. Ascioglu S, Rex JH, de Pau B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and haematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
68. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
69. Nivoix Y, Velten M, Letscher-Bru V et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-84.
70. Betts RF, Nucci M, Talwar D et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-84.
71. Cornely OA, Lasso M, Betts R et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60: 363-9.
72. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.
73. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27: 781-8.
74. Bruynesteyn K, Gant V, McKenzie C et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol 2007; 78: 532-9.
75. EMEA. Committee for medicinal products for human use - post-authorisation summary of positive opinion for Cancidas [WWW document]. URL, London [accessed on 25 September 2008].
76. Walsh TJ, Anaissie EJ, Denning DW. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
77. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
78. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
79. Kontoyiannis DP, Lewis RE, Lionakis MS, Albert ND, May GS, Raad II. Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: evidence of enhanced in vitro activity. Diagn Microbiol Infect Dis 2003; 47: 415-9.
80. Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002; 46: 3208-14.
81. Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents 2010; 35: 211-8.
82. Lafaurie M, Lapalu J, Raffoux E et al. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect 2010; 16: 1191-6.